←
Cytel Inc.5,631 posts
Cytel Inc. avatar

Cytel Inc.

@cytel

Shaping the future of drug development with software solutions, innovative consulting and proven clinical research services.

◷ Joined October 2012▧ 3,200 Photos and videos
Cytel Inc. avatar
Cytel Inc.@cytel·Oct 29

JCAs are changing how indirect comparative evidence must be generated and defended, and direct head-to-head data may not always be available or sufficiently aligned. MAICs can help address some of these evidence gaps — we discuss what makes them credible.  hubs.ly/Q04CJXX20

Post attachment
Cytel Inc. avatar
Cytel Inc.@cytel·Oct 28

In just one week, Cytel will be at the 2026 Bay Area Biotech-Pharma Statistics Workshop in Foster City! Book a meeting with a member of our team at BBSW here: hubs.ly/Q04CBHdq0 See you in Foster City! 👋

Post attachment
Cytel Inc. avatar
Cytel Inc.@cytel·Oct 27

While RCTs remain the cornerstone of regulatory and HTA decision-making, advances in computational science are creating entirely new forms of evidence. Dalia Dawoud discuses two of the most promising developments: in-silico data & MIDD. Learn more: hubs.ly/Q04CsXK00

Post attachment
Cytel Inc. avatar
Cytel Inc.@cytel·Oct 27

Cytel will be at PHUSE EU Connect 2026 in Glasgow! 📍 Stop by Booth 8 to speak with the Cytel team. See our upcoming presentations and book a meeting with a member of our team at PHUSE EU here: hubs.ly/Q04Crs7v0 See you in Glasgow! 👋

Post attachment
Cytel Inc. avatar
Cytel Inc.@cytel·Oct 26

Independent physician review is the cornerstone of endpoint adjudication, but much of an Endpoint Adjudication Committee's efficiency and effectiveness is determined long before before a physician ever opens a case. Learn more: hubs.ly/Q04C3D8l0

Post attachment
Cytel Inc. avatar
Cytel Inc.@cytel·Oct 22

NICE has published its AI Delivery Plan. Dalia Dawoud and Manuel Cossio discuss what HTA, HEOR, and market access professionals need to know and how sponsors can prepare as NICE's vision moves from experimentation to implementation. hubs.ly/Q04BR1nc0

Post attachment
Cytel Inc. avatar
Cytel Inc.@cytel·Oct 12

Join us at our SCOPE Europe Drinks Reception in Barcelona tomorrow evening! Meet the Cytel team and continue the conversations that matter most. Space is limited — please register early to secure your place. hubs.ly/Q04zSFkj0 We hope to see you there!

Post attachment
Cytel Inc. avatar
Cytel Inc.@cytel·Oct 8

Independent physician review is the cornerstone of endpoint adjudication, but much of an Endpoint Adjudication Committee's efficiency and effectiveness is determined long before before a physician ever opens a case. Learn more: hubs.ly/Q04zz3yg0

Post attachment
Cytel Inc. avatar
Cytel Inc.@cytel·Oct 7

Cytel will be at SCOPE Europe! Our team is ready to help you bring greater visibility and predictability to your next clinical trial through connected trial design and clinical data oversight. Book your meeting today: hubs.ly/Q04zl9FK0 We hope to see you there!

Post attachment
Cytel Inc. avatar
Cytel Inc.@cytel·Oct 5

How do you build an FSP workforce that controls costs without compromising quality, capability, or delivery? Join our experts for a webinar that explores how smarter workforce models can strengthen delivery, optimize resources, and create lasting value: hubs.ly/Q04z8JVD0

Post attachment
Cytel Inc. avatar
Cytel Inc.@cytel·Sep 30

Next week, the Cytel team will be in Denver at the 2026 CDISC US Interchange!   Stop by and say hello to our team at Booth 6.   See you in Denver! hubs.ly/Q04yHknc0

Post attachment
Cytel Inc. avatar
Cytel Inc.@cytel·Sep 29

How do you build an FSP workforce that controls costs without compromising quality, capability, or delivery? Join our experts for a webinar that explores how smarter workforce models can strengthen delivery, optimize resources, and create lasting value: hubs.ly/Q04y0Ndq0

Post attachment
Cytel Inc. avatar
Cytel Inc.@cytel·Sep 28

Cytel will be at SCOPE Europe! Our team is ready to help you bring greater visibility and predictability to your next clinical trial through connected trial design and clinical data oversight. Book your meeting today: hubs.ly/Q04yj8_m0 We hope to see you there!

Post attachment
Cytel Inc. avatar
Cytel Inc.@cytel·Sep 24

Workforce planning is often approached through the immediate needs of a role. But this can overlook something more fundamental. We discuss the broader questions sponsors should be asking to build teams that can continue to deliver well into the future. hubs.ly/Q04ybTWd0

Post attachment
Cytel Inc. avatar
Cytel Inc.@cytel·Sep 24

Parkinson’s disease is the second-most common neurodegenerative disease affecting over 11 million people globally. We discuss common endpoints used in clinical trials with an illustrative case study on how those endpoints may be analyzed. hubs.ly/Q04ybT_L0

Post attachment
Cytel Inc. avatar
Cytel Inc.@cytel·Sep 23

NICE has published its AI Delivery Plan. Dalia Dawoud and Manuel Cossio discuss what HTA, HEOR, and market access professionals need to know and how sponsors can prepare as NICE's vision moves from experimentation to implementation. hubs.ly/Q04y5PyW0

Post attachment